DALY II Japan/MB-CART2019.1 for DLBCL

Summary

DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.

Timeline

Start

2025-12-11

Primary completion

2027-01-31

Completion

2028-12-31

Drugs

Indications